Genolution Inc. (225220) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genolution Inc. (225220:KRX), powered by AI.

Current Price
₩1,810
P/E Ratio
-4.8
Market Cap
34.7B
Sector
Healthcare
What is the Genolution Inc. stock price forecast?

Genolution Inc. is currently trading at ₩1,810. View real-time AI analysis on Alpha Lenz.

What is Genolution Inc. insider trading activity?

View the latest insider trading data for Genolution Inc. on Alpha Lenz.

What is Genolution Inc.'s P/E ratio?

Genolution Inc.'s P/E ratio is -4.8.

Genolution Inc.

₩1.81K
KRX225220
Ask about Genolution Inc.'s future dividend policy...
Alpha Chat Insight

Genolution Inc. trades at a P/E of -4.8 (undervalued) with modest ROE of -8.1%.

Ask for details

Company Overview

Genolution Inc. is a biotechnology company that specializes in genetic research and development, primarily focused on enhancing precision medicine. The company's core function is to apply cutting-edge genetic engineering techniques to develop diagnostics, therapeutics, and vaccines. Genolution Inc. plays a pivotal role in the healthcare and pharmaceuticals sectors by providing innovative solutions that address complex genetic disorders. Their work is crucial for advancing personalized medicine, enabling tailored treatments based on an individual's genetic makeup. By engaging in collaborations with research institutions and other biotech firms, Genolution Inc. contributes to the broader scientific community and the ongoing evolution of healthcare innovation. With a commitment to improving patient outcomes and fostering scientific advancement, Genolution Inc. remains a key player in the global biotech market.

CEO김기옥
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

(FY 2024)

Profile

Market Cap₩34.73B
Revenue₩7.14B
Shares Out19.19M
Employees0

Margins

Gross33.18%
EBITDA-16.47%
Operating-128.42%
Pre-Tax-94.89%
Net-101.02%

Valuation

P/E-4.79
P/B0.41
EV/Sales4.58
EV/EBITDA-21.18
P/FCF-2.40

Growth (CAGR)

Rev 3Yr-53.90%
Rev 5Yr12.55%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-6.56%
ROE-8.14%
ROIC-5.78%

Financial Health

Cash & Cash Equivalents₩32.17B
Net Debt₩-6.12B
Debt/Equity32.41%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Genolution Inc. (Healthcare) Stock Forecast & Analysis ₩1,810 | Alpha Lenz